AR045217A1 - Sintesis regioselectiva de un ester de rapamicina (cci - 779) y compuestos intermediarios relacionados. - Google Patents

Sintesis regioselectiva de un ester de rapamicina (cci - 779) y compuestos intermediarios relacionados.

Info

Publication number
AR045217A1
AR045217A1 ARP040102778A ARP040102778A AR045217A1 AR 045217 A1 AR045217 A1 AR 045217A1 AR P040102778 A ARP040102778 A AR P040102778A AR P040102778 A ARP040102778 A AR P040102778A AR 045217 A1 AR045217 A1 AR 045217A1
Authority
AR
Argentina
Prior art keywords
rapamycin
ester
silyl
alkynyl
alkenyl
Prior art date
Application number
ARP040102778A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR045217A1 publication Critical patent/AR045217A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)

Abstract

La presente se refiere a síntesis regio selectiva de un éster de rapamicina. Se proveen también productos intermediarios. Reivindicación 1: Un proceso para preparar un 42-éster de rapamicina, que comprende: (a) acilar un 31-silil éter de rapamicina con un compuesto de fórmula HOOC:CR7R8R9 o uno de sus anhídridos mixtos, en los cuales: R7 es H, alquilo C1-6, alquenilo C2-7, alquinilo C2-7, -(CR12R13)fOR10, -CF3, -F, o -CO2R10; R10 es H, alquilo C1-6, alquenilo C2-7, alquinilo C2-7, trifenilmetilo, bencilo, alcoximetilo C2-7, cloroetilo o tetrahidropiranilo; R8 y R9 se toman juntos para formar X; X es un 2-fenil-1,3,2-dioxaborinan-5-ilo o un 2-fenil-1,3,2-dioxaborinan-4-ilo, en los cuales el fenilo puede estar sustituido en forma opcional; R12 y R13 son, cada uno en forma independiente, H, alquilo C1-6, alquenilo C2-7, alquinilo C2-7, trifluorometilo o -F; y f = 0-6; para dar un 42-éster boronato 31-silil éter de rapamicina; (b) hidrolizar en forma selectiva el 42-éster boronato 31-silil éter en condiciones levemente ácidas para dar un 42-éster boronato de rapamicina; y (c) tratar el 42-éster boronato de rapamicina con un diol apropiado para dar un 42-éster de rapamicina.
ARP040102778A 2003-08-07 2004-08-04 Sintesis regioselectiva de un ester de rapamicina (cci - 779) y compuestos intermediarios relacionados. AR045217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49324903P 2003-08-07 2003-08-07

Publications (1)

Publication Number Publication Date
AR045217A1 true AR045217A1 (es) 2005-10-19

Family

ID=34193170

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102778A AR045217A1 (es) 2003-08-07 2004-08-04 Sintesis regioselectiva de un ester de rapamicina (cci - 779) y compuestos intermediarios relacionados.

Country Status (26)

Country Link
US (1) US7153957B2 (es)
EP (1) EP1658295B1 (es)
JP (1) JP4227649B2 (es)
KR (1) KR20060057605A (es)
CN (1) CN1829722B (es)
AR (1) AR045217A1 (es)
AT (1) ATE365169T1 (es)
AU (1) AU2004265267A1 (es)
BR (1) BRPI0412667A (es)
CA (1) CA2532988A1 (es)
CO (1) CO5650251A2 (es)
CR (1) CR8189A (es)
DE (1) DE602004007145T2 (es)
DK (1) DK1658295T3 (es)
EC (1) ECSP066413A (es)
ES (1) ES2287772T3 (es)
IL (1) IL173134A0 (es)
MX (1) MXPA06000951A (es)
NO (1) NO20060494L (es)
PL (1) PL1658295T3 (es)
PT (1) PT1658295E (es)
RU (1) RU2339639C2 (es)
TW (1) TW200508241A (es)
UA (1) UA83245C2 (es)
WO (1) WO2005016935A2 (es)
ZA (1) ZA200601055B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085908A1 (en) 2001-04-24 2002-10-31 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
JP5576007B2 (ja) 2003-01-27 2014-08-20 エンドサイト・インコーポレイテッド ビタミン受容体結合性薬剤送達結合体
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
DK1701698T3 (da) * 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
EP1737869A1 (en) 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
CA2564811A1 (en) 2004-04-14 2005-10-27 Wyeth Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
ES2313328T3 (es) 2004-04-14 2009-03-01 Wyeth Procedimiento para la preparacion de 42-esteres de rapamicina y 32-esteres de fk-506 con acido dicarboxilico, precursores para conjugados de rapamicina y anticuerpos.
JP2007534337A (ja) * 2004-04-27 2007-11-29 ワイス ラパマイシン特異的メチラーゼを用いるラパマイシンの標識
JP5149620B2 (ja) * 2004-07-23 2013-02-20 エンドサイト,インコーポレイテッド 2価リンカーおよびその結合体
SV2006002188A (es) 2004-08-10 2006-03-15 Wyeth Corp Derivados de cci - 779 y metodos para su preparacion ref. am-101759salvo
WO2006050461A1 (en) 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
EP1856130A1 (en) 2005-02-09 2007-11-21 Wyeth a Corporation of the State of Delaware Cci-779 polymorph and use thereof
EP1853612A1 (en) 2005-03-02 2007-11-14 Wyeth Purification of rapamycin
WO2006093743A1 (en) * 2005-03-02 2006-09-08 Wyeth Recovery of cci-779 from mother liquors
WO2006101845A2 (en) 2005-03-16 2006-09-28 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト,インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
EP2374480A3 (en) 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
WO2007056175A2 (en) * 2005-11-04 2007-05-18 Wyeth 41-methoxy isotope labeled rapamycin 42-ester
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
RU2008120670A (ru) 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
KR20080077618A (ko) * 2005-12-07 2008-08-25 와이어쓰 정제된 결정체 cci-779 의 제조 방법
EP1962819A1 (en) * 2005-12-20 2008-09-03 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ580132A (en) * 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2011051960A2 (en) 2009-09-25 2011-05-05 Cadila Healthcare Limited Process for the preparation of rapamycin derivatives
AU2011210227A1 (en) * 2010-01-28 2012-08-30 Fresenius Kabi Oncology Ltd. Process for the preparation of Temsirolimus and its intermediates
CN102020661B (zh) * 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔合成方法
CN102020662B (zh) 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔制备方法
EP2694520A1 (en) * 2011-04-01 2014-02-12 Sandoz AG Regioselective acylation of rapamycin at the c-42 position
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドEndocyte, Inc. 非天然アミノ酸を含む薬物送達結合体および使用方法
CN104086564B (zh) * 2014-07-30 2019-02-05 江苏奥赛康药业股份有限公司 一种高纯度坦罗莫司的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives

Also Published As

Publication number Publication date
NO20060494L (no) 2006-03-06
RU2006106910A (ru) 2007-09-20
ES2287772T3 (es) 2007-12-16
JP2007501783A (ja) 2007-02-01
JP4227649B2 (ja) 2009-02-18
ECSP066413A (es) 2006-09-18
RU2339639C2 (ru) 2008-11-27
CR8189A (es) 2006-10-04
UA83245C2 (en) 2008-06-25
PT1658295E (pt) 2007-09-25
AU2004265267A1 (en) 2005-02-24
ZA200601055B (en) 2008-07-30
EP1658295A2 (en) 2006-05-24
CO5650251A2 (es) 2006-06-30
PL1658295T3 (pl) 2007-11-30
KR20060057605A (ko) 2006-05-26
WO2005016935A3 (en) 2005-04-07
CA2532988A1 (en) 2005-02-24
US7153957B2 (en) 2006-12-26
DK1658295T3 (da) 2007-09-24
EP1658295B1 (en) 2007-06-20
TW200508241A (en) 2005-03-01
MXPA06000951A (es) 2006-03-30
WO2005016935A2 (en) 2005-02-24
ATE365169T1 (de) 2007-07-15
US20050033046A1 (en) 2005-02-10
BRPI0412667A (pt) 2006-09-26
IL173134A0 (en) 2006-06-11
DE602004007145T2 (de) 2008-02-28
CN1829722A (zh) 2006-09-06
CN1829722B (zh) 2010-10-27
DE602004007145D1 (de) 2007-08-02
HK1085482A1 (en) 2006-08-25

Similar Documents

Publication Publication Date Title
CO5650251A2 (es) Sintesis regioselectiva de cci-779
ECSP066784A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos, asi como productos que las contienen
ECSP066829A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
CO6351774A2 (es) Agentes terapeuticos derivados de eter diglicidico y metodos para su uso
AR055635A1 (es) Uso de sulfonanilidas como herbicidas
PT1725537E (pt) Novos compostos como moduladores do receptor opióide
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
EA200801160A1 (ru) Алкоксиалкилзамещённые спироциклические тетрамовые и тетроновые кислоты
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR081577A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR082004A1 (es) Compuestos de fusion de piridina
AR043432A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
PE20161240A1 (es) Agentes anticancerosos y sus preparaciones
AR053047A1 (es) 1h-quinazolin-2,4-dionas como ligandos del receptor ampa
MX2013007296A (es) Derivado novedoso de isoquinolina sustituido.
IN2014MN00411A (es)
EA201171012A1 (ru) Производные 5-фторбензотиазолов и 5-фторбензимидазолов, содержащие 6-замещенный триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов met
PE20081360A1 (es) Compuestos analogos de lipoxina a4 para el tratamiento y prevencion de la fibrosis intestinal
AR045459A1 (es) Tiofenos sustituidos y usos de los mismos
AR084446A1 (es) Derivados de bifenilo y su uso en el tratamiento de enfermedades de la piel y de la cavidad bucal
AR045209A1 (es) 6-(1,1-difluoralquilo) -4- aminopicolinatos y su uso como herbicidas
ECSP088933A (es) Métodos para preparar derivados de ácido glutámico y sus intermedios
HN2009001484A (es) Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure